ArticleJournal of thoracic disease2024
Predicting prognosis of locally advanced esophageal squamous cell carcinoma through early changes in neutrophil-to-lymphocyte ratio following neoadjuvant immunochemotherapy.
Article in Journal of thoracic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Development of a predictive model for pathological complete response following neoadjuvant immunotherapy and chemotherapy in locally advanced resectable esophageal squamous cell carcinoma.World journal of surgical oncology · 2026Article
- The value of perioperative neutrophil-to-lymphocyte ratio combined with the prognostic nutritional index for predicting anastomotic leakage after minimally invasive esophagectomy.Journal of thoracic disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The effectiveness of neoadjuvant immunochemotherapy (NAIC) in locally advanced esophageal squamous cell carcinoma (ESCC) remains unclear. This study aims to validate the relation between early alterations in neutrophil-to-lymphocyte ratio (NLR) and clinical outcomes among individuals diagnosed with locally advanced ESCC undergoing NAIC. Methods: We retrospectively enrolled a cohort of ESCC patients who underwent NAIC at least 1 cycle between May 2020 and October 2021 at Guangdong Provincial People's Hospital. Blood tests were conducted both at the baseline and following the initial treatment cycle. We examined the correlation between NLR-Δ [(cycle 1 NLR - baseline NLR)/baseline NLR × 100%] and overall survival (OS) in ESCC patients. Results: Ninety-eight patients were enrolled in this study, with a median patient age of 62 years [interquartile range (IQR), 56.0-67.0 years]. The median baseline NLR was 2.63 (1.09-9.23). A total of 39 mortality events were observed after a median follow-up of 37.55 months. Thirty-three patients (33.67%) had NLR-Δ ≤-35%, while 65 patients (66.33%) had NLR-Δ >-35%, patients with NLR-Δ ≤-35% (N=33) exhibited significantly worse OS compared to patients with NLR-Δ >-35% (N=65) (median OS: 28.330 months Conclusions: Patients with a decrease in NLR value of more than 35% after the first cycle of immunochemotherapy may be associated with a worse clinical outcome in ESCC. NLR-Δ shows potential as an early-detection biomarker for NAIC-treated ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.